US2015050257A1PendingUtilityA1

Fibrosis causing agent

Assignee: TERUMO CORPPriority: Aug 19, 2013Filed: Aug 19, 2014Published: Feb 19, 2015
Est. expiryAug 19, 2033(~7.1 yrs left)· nominal 20-yr term from priority
A61P 43/00A61K 35/19A61K 9/007A61K 38/363A61K 31/734A61P 11/00A61K 47/02A61K 35/16A61K 45/06A61K 38/4833
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A fibrosis-causing agent is highly effective in the fibrosis of tissues. The fibrosis-causing agent contains a fibrosis inducer and a fibrosis promoter. A fibrosis-causing agent dosage form and a method of administering the fibrosis-causing agent is also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter. 
     
     
         2 . The fibrosis-causing agent according to  claim 1 , wherein the fibrosis promoter contains platelets or platelet-rich plasma (PRP). 
     
     
         3 . The fibrosis-causing agent according to  claim 2 , wherein the fibrosis promoter contains platelet-rich plasma (PRP) and a PRP gelling agent. 
     
     
         4 . The fibrosis-causing agent according to  claim 3 , wherein PRP gelling agent contains at least one selected from the group consisting of calcium, calcium salt, fibrin, fibrinogen, thrombin, vitamin K, and factor X. 
     
     
         5 . The fibrosis-causing agent according to  claim 1 , wherein the fibrosis inducer contains at least one polyanion. 
     
     
         6 . The fibrosis-causing agent according to  claim 5 , wherein the polyanion is at least one selected from the group consisting of alginic acid, alginate, and alginic ester. 
     
     
         7 . The fibrosis-causing agent according to  claim 1 , wherein the fibrosis-causing agent is administered for treatment of pulmonary emphysema. 
     
     
         8 . A method of causing fibrosis by administering to a patient in thereof, a fibrosis causing agent according to  claim 1 . 
     
     
         9 . A method for causing fibrosis by administering to a subject a fibrosis causing agent. 
     
     
         10 . The method according to  claim 9 , wherein the fibrosis causing agent comprises a fibrosis inducer and a fibrosis promoter. 
     
     
         11 . The method according to  claim 10 , wherein the fibrosis promoter contains platelets or platelet-rich plasma (PRP). 
     
     
         12 . The method according to  claim 11 , wherein the fibrosis promoter contains platelet-rich plasma (PRP) and a PRP gelling agent. 
     
     
         13 . The method according to  claim 12 , wherein PRP gelling agent contains at least one selected from the group consisting of calcium, calcium salt, fibrin, fibrinogen, thrombin, vitamin K, and factor X. 
     
     
         14 . The method according to  claim 9 , wherein the fibrosis inducer contains at least one polyanion. 
     
     
         15 . The method according to  claim 14 , wherein the polyanion is at least one selected from the group consisting of alginic acid, alginate, and alginic ester. 
     
     
         16 . A composition for treating pulmonary emphysema, the composition consisting of a fibrosis-causing agent, the fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter. 
     
     
         17 . A method for treating pulmonary emphysema by administering to a patient in need thereof, the composition according to  claim 16 . 
     
     
         18 . A fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter,
 the fibrosis promoter consisting essentially of platelets or platelet-rich plasma (PRP); and   the fibrosis inducer consisting essentially of at least one polyaninon.   
     
     
         19 . The fibrosis-causing agent according to  claim 18 , wherein the fibrosis promoter further comprises a platelet-rich plasma (PRP) gelling agent, the gelling agent is at least one selected from the group consisting of calcium, calcium salt, fibrin, fibrinogen, thrombin, vitamin K, and factor X. 
     
     
         20 . The fibrosis causing agent according to  claim 18 , wherein the polyanion is at least one selected from the group consisting alginic acid, alginate and alginic ester. 
     
     
         21 . A fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter, wherein
 the fibrosis promoter is platelet-rich plasma (PRP); and   the fibrosis inducer is calcium alginate.

Join the waitlist — get patent alerts

Track US2015050257A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.